Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial.
Won-Seog Kim, Huilai Zhang, Dai Maruyama, Astrid Pavlovsky, Eduardo M Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam J Olszewski, Joan Ashby, Shen Yin, Wahib S Ead, Martin Janousek, Song Pham, Connie L Batlevi, Michael C Wei, Jason Westin, Lihua E Budde
Clin Lymphoma Myeloma Leuk S2152-2650(26)04002-4
摘要
摘要
INTRODUCTION: Intensive lymphoma therapies can have significant impact on patient health-related quality of life (HRQoL), which is important to understand using patient-reported outcomes (PROs). This analysis reports PROs from the positive phase 3 SUNMO trial evaluating mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with autologous stem cell transplant (ASCT)-ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL). PATIENTS AND METHODS: Patients were randomized 2:1 to receive Mosun-Pola or R-GemOx. PROs were assessed using EORTC QLQ-C30, FACT-Lym LYMS, and FACT/GOG-NTX. Key PRO endpoints: time to deterioration (TTD), change in scores from baseline, and mixed-effects models with repeated measures. RESULTS: Of 208 randomized patients, questionnaire completion rates remained high (> 95%) throughout treatment. Baseline scores indicated mild-to-moderate symptom burden and functioning impairment. Baseline physical functioning was preserved for over 1 year longer with Mosun-Pola versus R-GemOx (TTD, 17.4 vs. 5.3 months; hazard ratio [HR] = 0.70). Longitudinal analysis revealed continuous improvement of physical functioning in the Mosun-Pola arm, which was consistent across older and younger age groups. Fatigue trajectories improved post cycle 2 in the Mosun-Pola arm, whereas patients in the R-GemOx arm reported continued deterioration. Mosun-Pola prevented worsening of lymphoma symptoms for longer than R-GemOx (TTD, 7.2 vs. 4.6 months; HR = 0.82). Low levels of baseline peripheral neuropathy were maintained in both arms, although Mosun-Pola extended the time without worsening of baseline peripheral neuropathy (TTD, 4.4 vs. 2.0 months with R-GemOx; HR = 0.71). CONCLUSION: Mosun-Pola provides profound HRQoL benefits, complementing its superior clinical efficacy and manageable safety profile in patients with ASCT-ineligible R/R LBCL. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05171647).
KM 提取结果
0 个 Figure · 0 个 KM 面板